EarlySight’s Post

Oxford Endovascular Closes GBP8M Series A+ Funding Customer Refocus 2024-05-20 FinSMEs Oxford Endovascular, an Oxford, UK-based medtech startup, closed an GBP8m in Series A+ funding round. The round was led by Parkwalk Advisors with participation from Norcliffe Capital, Oxford Science Enterprises (OSE), Vulpes and the University of Oxford. The company intends to use the funds to take its medical device, OXIFLOW, a step closer to a […] The post Oxford Endovascular Closes GBP8M Series A+ Funding appeared first on FinSMEs. <div><div><div><div><article><p></p><center> </center> <div> <p><a rel="noreferrer noopener" href="https://lnkd.in/eUEZRM-A" target="_blank"><strong>Oxford Endovascular</strong></a>, an Oxford, UK-based medtech startup, closed an GBP8m in Series A+ funding round. </p> <span></span> <p>The round was led by Parkwalk Advisors with participation from Norcliffe Capital, Oxford Science Enterprises (OSE), Vulpes and the University of Oxford. </p> <p>The company intends to use the funds to take its medical device, OXIFLOW, a step closer to a First-In-Human clinical study, and furter scale up operations. </p> <p>Led by Mike Karim, CEO, Oxford Endovascular is a spin-out from Oxford University, working to prevent brain haemorrhage by curing brain aneurysms, a condition that affects 1 in 50 persons. The company is advancing OxiFlow™️, a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, reducing the risk of complications. It conforms better to blood vessels making more patients treatable</p> <p><strong>FinSMEs</strong></p> <p>20/05/2024</p> </div><center> <p></p></center> </article></div></div></div></div>

🚀 Revolutionizing Deeptech in India! 🌟 Innovative deeptech startups in India are not just driving technological advancements but also tackling critical societal challenges. From Artelus' AI-driven health-tech solutions combating preventable blindness to GalaxEye's groundbreaking multi-sensor imaging satellites, these startups are leading the way. Niramai Health Analytix's non-invasive breast cancer screening device recently received US FDA clearance, and Azooka Labs is pioneering eco-friendly biotech solutions. With over 3,200 deeptech startups and substantial investments, the sector is set to contribute up to $500 billion to India's economy by 2025. 🌐 #DeepTech, #Innovation, #AI, #HealthTech, #Startups, #Technology, #TechRevolution, #IndiaStartups, #SocietalImpact, #Artelus, #GalaxEye, #Niramai, #AzookaLabs, #STEM, #DigitalTransformation,

Lithuanian startup gains €3M to expand AI-driven echocardiography solution across global markets Ligence, a Vilnius-based startup focused on cardiac diagnostics, has secured €3 million in seed funding, with Simpact Ventures leading the investment. Other contributors include Coinvest Capital, the European Innovation Council (EIC) Fund, Lemonade Stand, and angel syndicate NGL Ventures. The company has developed AI-powered software that automates the analysis of cardiac ultrasound images, aiming to support cardiologists in making more accurate and timely diagnoses. The funding will help Ligence expand its reach and further its mission to improve diagnostic processes, reduce the workload on healthcare professionals, and enhance patient care. https://lnkd.in/dFnXtqgu European Innovation Council and SMEs Executive Agency (EISMEA) #funding #balticmade #lithuania #startups #medtech #healthtech #trending

Danish startup raises €17.4 million to enhance MRI workflows amidst healthcare staffing shortages CEREBRIU has secured €17.4 million in Series A funding led by North Ventures, with ongoing support from Export and Investment Fund of Denmark (EIFO) and Sagitta Family Office. The investment will help Cerebriu scale its AI-powered MRI solution, Apollo, which improves MRI workflows by optimizing scan times and easing the burden on radiology departments. With this funding, the company plans to expand its product offerings and accelerate its global reach, aiming to address the rising demand for MRI exams amidst staffing shortages in healthcare systems worldwide. https://lnkd.in/d38mdUK3 #funding #nordicmade #denmark #startups #healthtech #medtech #trending

PitchBook's Q4 2023 Medtech Report just released with some great reflection on the dynamics of the Medtech industry in Q4 2023 and a look ahead to the promising trends of 2024, here are some key takeaways: 1️⃣ VC Funding Dynamics: Medtech VC funding experienced a slight stall in Q4, amounting to $2.6 billion compared to $3.0 billion in Q3. This represents a notable decline of over 25% from the $3.5 billion funding in Q4 2022. 2️⃣ Top Three Categories: In 2023, cardiovascular ($1.4 billion), surgical robotics ($932.7 million), and cancer diagnostics ($659.6 million) emerged as the top three categories receiving VC funding. The upcoming year, 2024, is poised to be a pivotal one for genomics, especially with the anticipated spin-off of Grail by Illumina and heightened competition from innovative players like Ultima Genomics and Element Biosciences. 3️⃣ Stock Performance and Market Dynamics: Following a challenging stock performance in Q3, primarily fueled by concerns regarding the impact of GLP-1 weight loss drugs on existing business models, medtech share prices rebounded and closely mirrored major indexes. Established medtech markets seem resilient in the face of rapid weight loss drug adoption. 4️⃣ Segment Trends: While the diagnostics segment appears primed for a rebound after a tough 2023, the life sciences & tools segment may continue to navigate moderate growth post-pandemic, with investors shifting focus towards higher-growth ventures. 5️⃣ Acquisitions and Exit Strategies: Q4 witnessed the acquisition of several medtech startups, signaling positive momentum. Moreover, there were notable $400 million-plus VC exits. However, the IPO landscape remained largely closed for medtech startups, potentially leading more companies to explore M&A as a viable exit strategy. The Medtech sector continues to evolve dynamically, presenting both challenges and opportunities. As we move forward into 2024, let's stay attuned to these trends, adapt to market shifts, and drive innovation that positively impacts healthcare worldwide.

October was a standout month for MedTech venture capital. Over $430M in funding was raised across these 15 groundbreaking innovations: eGenesis, Inc. – $191M Series D to scale human-compatible engineered organs and address the global organ shortage. INBRAIN Neuroelectronics – $50M Series B to advance AI-powered graphene-based brain-computer interfaces for personalized neurological therapies. Bright Uro – $32M Series A (oversubscribed) for wireless, catheter-free urodynamic monitoring systems to transform bladder health diagnostics. INNOVENTRIC – $28.5M Series B for a heart valve treatment innovation using a cross-caval approach for tricuspid regurgitation (TR). Vianautis – $25M Series A to develop cutting-edge polymer-based drug delivery systems for genetic therapies. ONWARD Medical – CHF 50M Series A to advance spinal cord injury treatments through spinal cord stimulation and brain-computer interfaces. Semble – $15M Series B to streamline healthcare administration with automated workflows and improved system interoperability. Sonavex – $15M Series A-2 to enhance vascular data collection in dialysis clinics, supporting AV fistula maturation. Lymphatica Medtech – €17.9M Series B to develop an implantable device for innovative lymphedema treatment. MARAbio – $19M Series A to launch the first-ever blood test for diagnosing Maternal Autoantibody Related Autism. Babson Diagnostics – Strategic investment from BD to scale diagnostic blood testing solutions. Kaminari Medical – €3.8M Seed for photoacoustic ultrasound tech to improve coronary artery assessments. SymPhysis Medical – $2.4M Seed to develop a less invasive treatment for malignant pleural effusion in late-stage cancer patients. Hyivy Health – $2M Seed to offer real-time monitoring and therapeutic interventions for pelvic health conditions. Definition Health – £5.75M Pre-Seed to improve surgical workflows and patient outcomes. With over $430M raised in MedTech venture capital in October alone, what’s next for 2025? Will AI, robotics, or something entirely new lead the charge in the next wave of investment? ------------------------------ I help MedTech innovators build impactful teams. DM if you want to learn more. #MedTech #VentureCapital #HealthTech #Innovation #Biotech #Healthcare #InvestmentNews #TechForGood #MedicalDevices #AIinHealthcare #SpinalCordInjury #OrganDonation #SurgicalTech #FundingSuccess #OctoberFunding

In my latest article published on MD+DI, I share tips from 5 startup #medtech CEOs on how to convince a variety of stakeholders on the path to getting your #medicaldevice to market. Highlights from this op-ed include: ➡️ Shyam Natarajan, CEO of Avenda Health, stresses why it’s important to never stop talking to end users in order to figure out the scale of the need you’re trying to solve. ➡️ Cecile Brosset Dubois, CEO of Sonio, talks about customizing your pitch to resonate with the diverse interests and priorities of potential investors. ➡️ Kelly Roman, CEO of Fisher Wallace Laboratories, Inc., elaborates on the exploration of fundraising and market opportunities through pilot study programs, crowdfunding, and other unconventional routes. ➡️ Patricia Zilliox, former CEO of EYEVENSYS, emphasizes the criticality of developing treatments that are not only scientifically sound but patient-friendly, too. ➡️ Eugene Malinskiy, CEO of Lazurite, tells his story about working closely with physicians during the earliest development stages in order to land on a product that serves the needs, preferences, and workflow of all end-users. For more actionable advice from these proven leaders, check out the full article here: https://lnkd.in/gtJG497C As always, thanks to Omar Ford, Amanda Pedersen, and Katie Hobbins for their publishing support! 🙌🏼

Coming at you is Scott Nelson’s recent MD+DI op-ed that explores how 5 #medtech CEOs successfully convinced key stakeholders — regulators, capital partners, and end-users — throughout their startup’s journey. Dive right in by clicking on the link below. 👇🏼

Here are some tried and true lessons that Scott Nelson summarised in a recent op-ed for MD+DI. In this article, he explores how #medtech startups can move from idea to commercialization and what it takes to convince key stakeholders along the way. In addition to the 5 key learnings he shares from other #medicaldevices entrepreneurs, Scott also touches on: 🪺 Strategies for gathering evidence and that can help inform your decisions. 🎨 The power of storytelling in all stages of a startup. 🔩 Using prototypes to demonstrate the viability of your idea. Click on the link ⬇ to check out the full article.

CytoVeris is honored to be selected as a part of the 2024 MedTech Innovator cohort – MedTech Innovator is the world’s largest accelerator of medical technology companies: This was a particularly competitive year, with around 1,400 applying for approximately 65 spots in this year's final cohort.  Explore the full list of participating companies here: https://lnkd.in/eq8zbHmR We look forward working with industry experts to further our mission to bring enhanced tissue ID and cancer margin visualization to MIS & robotic procedures. #MedTechInnovator #CytoVeris #Cancersurgery #AI #Labelfree #autofluorescence #cancermargin#multispectral #intraoperativeimaging #Advancedvisualization #Precisionsurgery #metech #cancerdetection#enhancedimaging #roboticsurgery